Metagenomi Therapeutics, Inc. (NASDAQ: MGX) disclosed a recent insider transaction involving its President and Chief Executive Officer, Jian Irish. On June 5, 2026, Irish executed a sale of 3,737 shares of the company's common stock. The transaction resulted in total proceeds of $4,854, calculated based on a share price of $1.299. This sale was not a discretionary move but an automatic mechanism designed to cover tax withholding obligations associated with the vesting of restricted stock units granted to Ms. Irish. The relevant vesting events were linked to grants issued on April 1, 2024, and April 1, 2025.
Following this automatic sale, Ms. Irish's direct holdings in Metagenomi Therapeutics common stock stand at 377,533 shares. This total includes 1,500 shares acquired through the company's employee stock purchase plan on May 29, 2026. Furthermore, Ms. Irish maintains indirect beneficial ownership through two separate irrevocable trusts. She holds 292,714 shares through the Bruce Irish 2023 Irrevocable Trust, FBO Jian Irish, and 292,713 shares through the Jian Irish 2023 Irrevocable Trust. Ms. Irish disclaims beneficial ownership of these indirectly held securities except to the extent of her pecuniary interest.
The transaction was formally reported in a Form 4 filing submitted to the Securities and Exchange Commission on June 10, 2026. At the time of the filing, Metagenomi's stock was trading at $1.26 per share. This price point sits near the company's 52-week low of $1.21 and reflects a 7.5% decline over the preceding week. Market data indicates the stock is currently trading at $1.26, up $0.03 or 2.43% in real-time data as of 11:24:22 USD.
Metagenomi Therapeutics has recently been the subject of notable analyst and clinical developments. Wells Fargo adjusted its price target for the company, reducing the outlook from $12.00 to $9.00. Despite this downward revision, the firm maintained an Overweight rating on the shares. This adjustment coincides with the company's progress on MGX-001, a therapy for Hemophilia A. An Investigational New Drug (IND) filing is expected in the fourth quarter of 2026, with a Phase 1/2 trial initiation planned for 2027.
Additionally, Metagenomi announced a significant publication in Nature Structural & Molecular Biology. The study highlights MG119-28, a compact CRISPR nuclease that exhibits enhanced genome editing efficiency compared to previously identified nucleases. The research attributes this improved performance to the nuclease's superior structural stability and more stable guide RNA, leading to faster DNA cleavage activity. According to InvestingPro analysis, the stock appears undervalued at current levels, with additional insights available for subscribers.